Plant Name: Zea mays
Taxonomic Information:
Plant ID: NPO15810
Plant Latin Name: Zea mays
Taxonomy Genus: Zea
Taxonomy Family: Poaceae
Plant External Links:
NCBI TaxonomyDB:
4577
Plant-of-the-World-Online:
426810-1
Used in Medicines:
Country/Region:
Turkey; Canada; Madagascar; Italy; Turkmenistan; Lebanon; Syrian Arab Republic; Swaziland; Argentina; Burkina Faso; Ghana; Israel; Togo; Zimbabwe; Jordan; Chile; Thailand; Iraq; Nigeria; Philippines; Indonesia; United States; Russia; Brazil; Romania; Angola; Portugal; Mexico; South Africa; India; China; Kenya; South KoreaTraditional Medicine System:
Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyMedicinal Functions:
Cancer; Cholagogue; Demulcent; Diuretic; Hypoglycaemic; Hypotensive; Lithontripic; Stimulant; Vasodilator; Warts
Geographical Distribution:
Canada; Turkmenistan; Cambodia; Ethiopia; Swaziland; Argentina; Bolivia; Cameroon; Burkina Faso; Ghana; Guatemala; Germany; Spain; Netherlands; Jamaica; Oman; Tanzania; Seychelles; French Guiana; Yemen; Pakistan; Albania; India; Kenya; South Korea; Tajikistan; Turkey; Afghanistan; Bangladesh; Cyprus; France; Syrian Arab Republic; Rwanda; Somalia; Peru; Laos; Vanuatu; Cote d'Ivoire; Benin; Cuba; Togo; China; Dominican Republic; Ukraine; Indonesia; Mauritius; Belarus; Mali; Russia; Bulgaria; United States; Romania; Angola; Portugal; South Africa; Nicaragua; Austria; Vietnam; Mozambique; Japan; Niger; Brazil; Guinea; Costa Rica; Bahamas; Ireland; Nigeria; Ecuador; Australia; Algeria; Chile; Belgium; Thailand; Haiti; Belize; Sierra Leone; Georgia; Gambia; Poland; Morocco; Guinea-Bissau; Switzerland; Iraq; Chad; Uruguay; Mexico; Lebanon; Uzbekistan; Tunisia; Djibouti; Colombia; Burundi; Fiji; Madagascar; Italy; Sudan; Nepal; Israel; Zambia; Papua New Guinea; Zimbabwe; Jordan; Kazakhstan; Philippines; New Caledonia; Trinidad and Tobago; Hungary; Honduras; Myanmar; Equatorial Guinea; Egypt; United Kingdom; Greece; Sri Lanka; Comoros
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR1B; HTR1D; HTR2A; HTR2C; HTR6; | |
| TSHR; | |
| CA2; CA4; CA12; CA7; | |
| MPO; | |
| PTGS2; ALOX5; | |
| TP53; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.163E-11 | 6.330E-08 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.163E-11 | 6.330E-08 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.349E-10 | 4.241E-07 | HTR1B, HTR1D, HTR2A, HTR2C |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.569E-10 | 1.516E-06 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.376E-08 | 5.175E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.453E-08 | 9.134E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 7.290E-07 | 6.902E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 7.290E-07 | 6.902E-04 | HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:1903409; reactive oxygen species biosynthetic process | 1.133E-06 | 9.868E-04 | CYP1A1, CYP1B1, MPO |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.289E-06 | 1.052E-03 | CYP1A1, HTR2A, MPO, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 1.350E-06 | 1.052E-03 | ALOX5, CA12, CA2, CA4, CA7, CYP1A1, CYP1B1, TP53 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 2.040E-06 | 1.433E-03 | HTR1B, HTR1D, HTR2A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.186E-06 | 1.488E-03 | CA2, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 3.609E-06 | 2.245E-03 | HTR1B, HTR1D, HTR2A, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.095E-06 | 2.308E-03 | CYP1A1, CYP1B1, MPO, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 7.279E-06 | 3.372E-03 | HTR2A, HTR2C |
| BP | GO:0050896; response to stimulus | GO:0009266; response to temperature stimulus | 7.686E-06 | 3.487E-03 | HTR1B, HTR2A, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 1.785E-05 | 6.590E-03 | HTR2A, HTR2C, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.917E-05 | 6.788E-03 | CYP1A1, CYP1B1, HTR1B, HTR1D, TP53 |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 2.282E-05 | 7.645E-03 | HTR1B, HTR1D, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.322E-05 | 7.660E-03 | CA2, CYP1A1, HTR1B, MPO, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.414E-05 | 7.846E-03 | CA2, CYP1A1, CYP1B1, HTR1B, PTGS2, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.785E-05 | 8.542E-03 | CA2, CA7, HTR2A, HTR2C |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.267E-05 | 9.746E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.267E-05 | 9.746E-03 | CYP1A1, CYP1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.652E-12 | 1.883E-10 | HTR6, ALOX5, HTR1D, HTR1B, HTR2C, HTR2A, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.030E-08 | 1.425E-06 | ALOX5, CYP1A1, CYP1B1, PTGS2 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 7.280E-08 | 1.425E-06 | HTR6, HTR1D, HTR1B, HTR2C, HTR2A, TSHR |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.442E-10 | 2.997E-08 | CA12, CA2, CA4, CA7 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.045E-05 | 2.904E-04 | HTR6, HTR1D, HTR1B, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.334E-05 | 5.128E-04 | CYP1A1, CYP1B1, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 4.443E-04 | 3.943E-03 | HTR6, HTR2C, HTR2A |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.204E-04 | 4.106E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.019E-03 | 7.055E-03 | PTGS2, TSHR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.703E-04 | 1.727E-03 | CA2, CA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.248E-03 | 7.384E-03 | ALOX5, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.889E-03 | 9.580E-03 | CYP1B1, PTGS2, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.093E-03 | 7.055E-03 | CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.725E-03 | 9.420E-03 | CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; HTR1B; HTR1D; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; ALOX5; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; ALOX5; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1B; HTR1D; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2C; HTR6; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; ALOX5; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; ALOX5; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; HTR6; HTR1B; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; PTGS2; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Addiction | NA | HTR2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PTGS2; ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR1D; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
